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Abstract
Background: Attempts at gene therapy for the pulmonary manifestations of Cystic Fibrosis have
relied mainly on airway delivery. However the efficiency of gene transfer and expression in the
airway epithelia has not reached therapeutic levels. Access to epithelial cells is not homogenous for
a number of reasons and the submucosal glands cannot be reached via the airways.
Presentation: We propose that injecting gene delivery vectors directly into bronchial arteries
combined with pre-delivery of vascular endothelial growth factor to increase vascular endothelial
permeability and post-delivery flow reduction by balloon occlusion. Thus it may be possible to
reach mucous secreting cells of the bronchial luminal epithelium and the submucosal glands in an
increased and homogenous fashion.
Testing: This combination of techniques to the best of our knowledge has not previously been
investigated, and may allow some of the current limitations of gene therapy for Cystic Fibrosis to
be overcome.
Background
Cystic fibrosis (CF) is the commonest, severe autosomal
recessive disease in the UK, occurring in one child out of
every 2500 new-borns. The disease is caused by mutations
in the Cystic Fibrosis Transmenbrane Conductance Regu-
lator (CFTR) gene, leading to production of defective
CFTR protein, which disrupts chloride transport resulting
in markedly impaired water fluxes across various epitheli-
al layers. This leads to 'sticky' mucous secretions which
obstruct the secretory glands of the lungs, digestive tract
and other organs. In spite of considerable advances in the
treatment of the intestinal symptoms, comparatively less
progress has been achieved in the management of CF lung
disease.
Airway Delivery
To date, almost all attempts at gene therapy for the pul-
monary manifestations of CF have relied on vector deliv-
ery via the airways. This work in animal models and
human trials has demonstrated the ability to deliver genes
by non-viral and viral gene transfer vectors to the airway
epithelia by methods of inhalation, spray or broncho-
scopic delivery. Although these investigations demon-
strated that the general strategy of gene therapy for CF is
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hopeful, they also showed that the efficiency of even the
presently most effective vector system, adenovirus, is still
disappointingly low [2–9]. For adenovirus, this inefficien-
cy is specifically due to the scarcity of the adenovirus fibre
knob binding receptors: coxsackievirus and adenovirus re-
ceptor (CAR) and the absence of α vβ 3 and α vβ 5 integrins,
on the apical side of differentiated airway epithelia [10–
16]. In addition, the glyoxalin components (particularly
tethered mucins) of the apical cell surface of the airway
epithelia appear to be strong barriers to adenoviral gene
transfer [11] and these are ultimately secreted in the
'sticky' mucous, which is also an effective hindrance for
access to vectors. Furthermore the deeper submucosal
glands which express high levels of CFTR [17] play a criti-
cal role in the development of respiratory disease in CF
[18] and yet are almost impossible to reach from the air-
way lumen [19]. The basal cells which are important pro-
genitors of the bronchial epithelium are also not exposed
to the airway lumen and are concentrated more heavily in
the larger bronchi.
Intravenous Delivery
Considering the non-airway studies; intravenous vector
delivery has been studied in mice but has resulted pre-
dominantly in alveolar gene transfer and only low level
gene delivery to the upper airway epithelia [20]. This is be-
cause the pulmonary arterial route serves the areas of the
lung between the terminal bronchioles and alveoli, rather
than the bronchii where mucous is mainly produced. Us-
ing thoracotomy and pulmonary arteriotomy of the left
pulmonary artery in rats, again disappointingly low levels
of transgene expression (1% to 8% of total left lung cells)
have been found using an adenoviral vector. Of these
cells, between 2% and 50% were airway epithelia and be-
tween 38% to 94% were alveolar epithelial cells depend-
ing on the animal. Lemarchand et al. have infused
adenoviral vectors (Ad.RSVβ gal) directly into the pulmo-
nary circulation of sheep [21]. After 15 minutes of dwell
time, where both pulmonary arteries and veins were oc-
cluded, they unexpectedly found β -Gal expression in
bronchial and alveolar epithelium including the epitheli-
um of submucosal glands. They postulated gene delivery
to have occurred via the numerous anastomoses between
the pulmonary and bronchial circulations, but were una-
ble to determine how the vectors had crossed the epitheli-
al basal membrane, thought to be relatively impermeable.
The expression was patchy and did not occur in all ani-
mals (none in 4 of 17). A direct bronchial artery approach
may however improve on this initial success particularly
with the use of adjuvant techniques to increase vascular
permeability. These pathophysiological considerations
highlight why delivery of vectors targeting the systemic ar-
terial route, via the bronchial arteries to the mucous pro-
ducing bronchial airways should be attempted to
overcome the current limitations of gene therapy vector
delivery for CF lung disease. To the best of our knowledge
this specific approach has not been investigated however
we are aware of a number of other groups who are also
planning experiments along these lines, but have yet to
address issues of permeability of the vascular barriers.
Presentation of the Hypothesis
We suggest delivery of gene transfer vectors into the bron-
chial arteries (initially in a sheep model) with pre-delivery
of vascular endothelial growth factor and post delivery
sub-total flow occlusion, to enhance vascular permeabili-
ty and increase vector dwell time respectively. We suggest
this may allow the vectors to reach the bronchial epitheli-
um and sub-mucosal glands efficiently and with a high
degree of homogeneous gene transfer. This should enable
therapeutic expression levels of CFTR. In addition we as-
sume that the so far unidentified stem cells of the respira-
tory epithelium which reside preferentially in the cell
layer close to the basal lamina of the bronchial epithelia
will also be transfected.
Testing the Hypothesis: Delivery via Bronchial Arteries
A non-animal ex vivo model of a complete lung is current-
ly unavailable. Of the possible animal models, sheep have
lungs closest to human anatomy and physiology [22,23]
and have been extensively used for the study of the bron-
chial circulation physiology, tolerating vascular studies
well in experienced hands. In sheep, the bronchial artery
arises as a single large carinal vessel that supplies 80% of
the systemic flow to both lungs. The ostial diameter of this
artery varies from 1–6 mm and would accept 5 French
guiding catheters for vector delivery. The artery descends
into the lung supplying blood via branches to the main
and minor bronchi up to the distal terminal bronchioles
providing a rich peribronchial capillary plexus of thin ves-
sels (5–20 µm in diameter) which lies just below the res-
piratory epithelium in the sub-mucosa surrounding the
mucous secreting glands. At the microscopic level the
bronchial artery branches are histologically distinct from
their pulmonary arterial counterparts in that they have no
clearly defined external elastic lamina. The endothelium
of these arterioles is of the fenestrated type and investiga-
tors have demonstrated the passage of fluid from the arte-
rioles into the bronchial mucosa, as well as the passage of
neutrophils across the capillaries via active transport
through endothelial cell junctions. These anatomical fac-
tors highlight why vectors delivered via the bronchial ar-
teries should have an excellent chance of reaching the sub-
mucosal layer of all bronchii and thereby all target cells.
Applicability of the Bronchial Artery approach in humans
Bronchial arterial catheterisation in humans via a percuta-
neous approach has been practiced for 33 years, initially
for direct chemotherapy treatment for bronchial malig-
nancies and then for the embolisation of patients with se-BMC Pulmonary Medicine 2002, 2 http://www.biomedcentral.com/1471-2466/2/2
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vere haemoptysis. The safety issues that have arisen during
these procedures include inadvertent occlusion or embol-
isation into the anterior spinal artery which in a small per-
centage (highest 5%) of humans arises from one of the
branches of the bronchial arteries [24,25]. Catheterisation
itself carries a less than 1% mortality in human coronary
angioplasty series with well defined risks. Finally the is-
sues of oedema due to arterial engorgement and immune
response to the vectors must be quantified at various dos-
ages and volumes by histological examination. The issue
of systemic spill over of vector material into the cardiac
atria and thereafter into the systemic circulation would
need to be evaluated by sampling local and distant or-
gans. Nevertheless bronchial artery catheterisation is an
established technique amongst vascular interventionists
and the extension of this hypothesis for cystic fibrosis pa-
tients would be feasible particularly as their bronchial ar-
teries are considerably dilated [26]. Progress is also
continually being made in minimally invasive cardiac in-
terventions in the fetus and therefore the delivery to the
fetal bronchial arteries may become feasible in the future
[27].
Adjuvant techniques for improving Vascular Permeability
Despite the anatomical advantages, the following adju-
vant techniques may be needed to increase transvascular
vector delivery.
1. Increase Dwell Time
Maintaining bronchial artery sub-total occlusion for brief
periods would increase vector transfer to the bronchial tis-
sue and a reduced total flow mediated wash out of the vec-
tor into the heart. Such flow interventions using
angioplasty balloons to reduce forward flow can be main-
tained for lengthy periods by choosing the appropriate
balloon diameter without tissue or vessel injury. A degree
of interventional experience is needed here.
2. Increased Permeability of the Vascular Endothelium
Histamine increases permeability of both the bronchial
and pulmonary vessels at the level of the microcirculation
beds, probably acting on post-capillary venules where in-
tracellular junctions are opened to cause this effect [28–
30]. Vascular Endothelial Growth Factor increases micro-
vessel permeability to plasma proteins with 50,000 times
higher potency than histamine [31]. This growth factor
causes early hyperpermeability probably by vesico-vacu-
olar organelles and transcellular pores [32] within min-
utes. These vesico-vacuolar organelles span a range of
sizes from 60 to well over 300 nm [33]. Permeability is in-
creased to the extent of allowing erythrocyte and colloidal
carbon to pass, which are far greater in size than adenovi-
ral vectors (300 nm). Although this may cause oedema,
clinically in work by Isner and colleagues [34] on muscu-
lar administration of vascular endothelial growth factor,
this was rarely significant and responded to Frusemide.
Vectors for Gene Delivery through the Arterial route
Ideally one would wish to use a vector system which could
provide long term or even permanent gene delivery and
preferentially also target the stem cell population of the
airway epithelia. This would provide a basis for constant
renewal of epithelium with a corrected cell population
and obviate the need for repeated gene delivery. Retrovi-
ral, lentiviral and adeno-associated viral vectors could ful-
fil this requirement but relatively little is presently known
about their ability to infect the airway epithelia in vivo.
Implications of the Hypothesis
On a practical basis, to demonstrate proof of principle for
successful and consistent vector delivery to the target cells
from the basolateral side by delivery via the bronchial ar-
teries an adenovirus vector expressing a marker gene such
as beta-galactosidase could be used as first choice. At a lat-
er stage CFTR expressing vector systems would be used.
New international developments such as the elimination
of all the adenovirus structural genes from this vector sys-
tem are most likely to overcome to a large extent its
present immunological problems. However, long term
correction of cystic fibrosis will most likely require appli-
cation of one of the above mentioned integrating vector
systems.
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